Abstract. The revised 2016 World Health Organization classification introduced Erdheim-Chester disease (ECD) as a provisional entity within the histiocytic and dendritic cell neoplasms separate from the juvenile xanthogranuloma family based on distinct molecular features. However, evolving knowledge regarding the molecular and genetic aberrations in addition to common clinical features of ECD support the classification of ECD together with Langerhans cell histiocytosis (LCH). Accordingly, ECD can be thought of as an inflammatory myeloid clonal disorder based on the detection of various activating mutations along the mitogen activated protein kinase-extracellular signal regulated kinase (MAPK-ERK) pathway with most notable variant being a valine to a glutamic acid substitution at amino acid 600 in the B-rapidly accelerated fibrosarcoma protein (BRAFV600E). In this group, targeted therapy with a B-Raf inhibitor alone or combined with a MAPK-ERK (MEK) inhibitor has shown promising results based on several case reports. Currently, two phase II trials with BRAF inhibitors are underway and could potentially change the standard of care. MEK inhibitors may also be efficacious in ECD harboring mutations in MAP2K1; other potential targetable aberrations include programed cell death receptor 1 and mutations in phosphoinositide 3-kinase.
Erdheim-Chester disease (ECD) is a rare form of nonLangerhans cell histiocytosis (LCH) characterized by xanthogranulomatous infiltration of multiple organs by lipidladen histiocytes (1) . The first two cases were described by pathologists Jacob Erdheim and William Chester in 1930, but the term ECD was not used until 1972 when Ronald Jaffe reported a third case (2, 3) . The number of patients with ECD cited in the literature has risen steadily over the past decade and currently comprises approximately 600-700 cases (4) . Histiocytes in this disease are characteristically CD68 + and CD1a − , the latter distinguishing ECD from LCH (Table I) . This distinction however, noted in the prior classification, is currently under reconsideration following the 2016 revision of World Health Organization (WHO) classification of the Hematopoietic and Lymphoid Tissues. The WHO introduced ECD as a provisional entity under histiocytic and dendritic cell neoplasms, noting the association with B-rapidly accelerated fibrosarcoma gene (BRAF) mutations and the distinction from other members of the juvenile xanthogranuloma family (JXG) (5) . A growing understanding of the underlying pathology driving ECD has recently shifted our understanding of this rare disease entity and led to the introduction of targeted molecular therapies as an alternative to conventional treatments with chemotherapy, glucocorticoids, and interferon. This article is an update to our previous publication and will highlight the most recent knowledge regarding pathogenesis and treatment advances (6).
Etiology and Pathogenesis
The pathogenesis of ECD is a subject of debate, with increasing evidence arguing for a clonal neoplastic process versus an inflammatory disease (1) . Generally, the pathogenesis involves an intricate network of molecular pathways that ultimately result in systemic recruitment and activation of histiocytes. Identification of chemokines monocyte chemoattractant protein 1 and interleukin (IL) 8, that are regulated by tumor necrosis factor alpha (TNFα) in ECD lesions was first reported by Stoppacciaro et al. (7) . More recent studies have also shown high levels of systemic pro-inflammatory cytokines interferon alpha (IFNα), IL1, IL6, IL12 and MCP1. A single-center case series involving 37 patients with active untreated ECD relative to healthy controls showed a significant (p<0.05) 16-fold increase in IL6, 5.3-fold increase in IFNα, 2.3-fold increase in IL12, and 2-fold increase in MCP1 (8) . These molecules are known to play a role in T-helper 1 cell differentiation and activation necessary for systemic chemokine signaling. This study also proposed the notion of a 5-cytokine signature for ECD based on the observation that IFNα, IL12, MCP1, IL4 and IL7 were noted to be elevated in all of the untreated patients with ECD with active disease but not in the healthy controls nor in more common inflammatory diseases such as rheumatoid arthritis, systemic sclerosis and idiopathic inflammatory myopathies.
Discovery of activating mutations along the rat sarcoma (RAS) kinase cascade have altered our understanding of the biology of ECD. To date, the most clinically relevant activating mutation is BRAFV600E which is present in approximately 57-75% of cases (9) . B-Raf is a serine/threonine protein kinase which functions to phosphorylate MAPK/ERK kinase (MEK); amino acid substitutions in B-Raf resulting in uncontrolled cell growth via the mitogen activated protein kinase-extracellular signal regulated kinase (MAPK-ERK) pathway. This mutation has been reported with varying frequency in several malignancies, most notably melanoma, hairy cell leukemia, papillary thyroid cancer and colorectal carcinoma. Other activating mutations along the RAS pathway are found upstream in the MAPK cascade and involve neuroblastoma-RAS protooncogene (NRAS), RAS, rapidly accelerated fibrosarcoma (RAF), MAPK-ERK and phosphatidylinositol 3-kinase-lymphokineactivated killer T-cell-originated protein kinase (PI3K-AKT) (10). Emile et al. identified 80 patients with ECD who were wild-type for BRAFV600E and found that 10.9% had Phosphatidylinositol 3-Kinase Catalytic Subunit Alpha (PI3KCA) mutations and 3.7% had NRAS mutations (11) . In the future, targeted therapies for the PIK3A pathway might show promising results similar to treatment with BRAF and MEK inhibitors in those with BRAFV600E. Overexpression of cell-cycle regulators have also been identified in ECD lesions. Immunohistochemical analysis of 24 patients with various histiocytic diseases found an increased expression of programed cell death receptor ligand 1 (PDL1) in three out of four patients with ECD, seven out of eight patients with LCH, all three patients with follicular cell dendritic sarcoma, and in the single patient with histiocytic sarcoma (10) . PDL1 is a ligand that binds the T-cell co-inhibitory programed cell death receptor 1 (PD1), leading to the inhibition of cytotoxic activity and allowing for cell-cycle progression. Targeted therapies against PD1 and PDL1 are currently being used in the (11, 13, 14) . Haroche et al. evaluated the prevalence of BRAF mutations in 127 patients with several histiocytic disorders including ECD, LCH, Rosai-Dorfman disease, JXG, histiocytic sarcoma, xanthoma disseminatum, interdigitating dendritic cell sarcoma, and necrobiotic xanthogranulom. Samples from 97 patients were available for BRAFV600 sequencing, with the mutation detected in 54% (13/24) of patients with ECD, 38% (11/29) of patients with LCH and in none of the other histiocytic disorders (15) . This common clonal aberrancy noted in both disorders challenges our classification system and argues for possible overlap in pathogenesis between both diseases. Emile et al. furthered the link with the observation of mixed ECD-LCH histology in 23 patients. LCH was either diagnosed concomitantly or preceded the histological diagnosis of ECD. LCH involvement was determined by the typical histological findings of granulomas infiltrated by histocytes staining positively for CD1a or S100, while ECD was diagnosed histologically in 18 patients with foamy histiocytes nested around polymorphic granuloma, fibrosis or xanthogranulomatosis, and immunochemical identification of CD68 + or CD1a − cells; or clinically in five patients with typically symmetric bone presentation on positron emission tomography (PET) with organ involvement. BRAFV600 mutation was detected in 69% and 82% of LCH and ECD biopsies, respectively. This series reported the presence of LCH in 20% of patients with ECD, with some biopsies harboring both histological types within the same tissue (16) .
Treatment
Clinical response to treatment in ECD is widely variable, underscoring the great degree of complexity of this disease. Initial regimens involved corticosteroids, cytotoxic agents and radiotherapy, but have since shifted to favor IFNα as the standard of care. Hence, increasing clinical experience has shed light on the limited efficacy, resistance and side-effect profile of this agent and led to the search for alternative treatments. Therapies have expanded to include targeted therapy against BRAF, IL1 antagonists, and inhibitors of MEK, TNFα or tyrosine kinases. Given the rarity of this disease, efficacy data are limited to case reports and small case-series but larger long-term studies are underway.
Interferon-α
IFNα is one of the most well studied therapies in the treatment of ECD. Standard dosing ranges from 3-9 million IU administered three times per week (17) . One of the largest multi-center prospective cohort studies using IFNα and pegylated IFNα included 53 patients and was performed by Arnaud et al. Patients enrolled in this study had high-risk disease, with >50% having skeletal, cardiovascular, retroperitoneal, central nervous system with/without pulmonary involvement. IFNα was given at a maximum dose of 3 million IU three times a week or pegylated IFN at a dose of 135 mg once per week. The median follow-up duration from time of diagnosis was 37.6 months (range=0.70-188.7 months) and the 1-and 5-year survival rates were 96% and 68%, respectively. Using a Cox proportional hazard model, they found a hazard ratio of 0.32 with a 95% confidence interval of 0.14-0.70 (p=0.006) concluding that treatment with IFNα was an independent predictor of increased survival (18) . Patients with suboptimal response to standard dosing have been studied at higher dose regimens. Hervier et al. conducted a prospective trial of 24 patients with extensive disease involving the CNS with/without cardiac involvement who had suboptimal response to standard IFNα dosing. IFNα was given at an increased dose of >18 mlU once weekly and pegylated IFNα at >180 mg once weekly; the study reported improved disease in 46% of patients, stable disease in 21% of patients, and worsened disease in 25% of patients with a follow-up of up to 3 years (19).
IL1 Receptor Antagonist
Anakinra is an IL1 receptor antagonist approved for the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease. Its mechanism of action in ECD is extrapolated from the knowledge that proinflammatory cytokines, including IL1, are produced after IFNα stimulation. In one of the first reports, Aouba et al. reported complete regression of disease after 3-6 months in two patients with bony lesions and periureteral fibrosis treated with 100 mg anakinra per day. Cohen-Aubart et al. published the largest retrospective analysis using anakinra in 12 patients with diffuse disease involving the long bones, heart, retro-orbit and/or meninges and who were intolerant to or whose disease progressed on therapy with IFN. Out of the 12 patients, nine completed the treatment course of 100 mg anakinra administered subcutaneously daily for 22 months. Symptomatic improvement was reported in 50% of the patients in regard to fatigue, bone pain, fever, and sinus disturbances, but no significant difference in lowering the Creactive protein level. Furthermore, five patients had progression of disease, two had stable disease, one had a partial response and one had complete response (20) . Pain at the injection site, edema and headache were the most frequent reported adverse events, with a 33% rate of treatment discontinuation due to intolerance. Considering the variable response to anakinra, future studies are needed to delineate at which stage and severity of this disease the agent would be most applicable.
BRAF Inhibitors
Vemurafenib is a BRAF inhibitor approved in 2011 by the Food and Drug Administration for the treatment of advanced melanoma in patients harboring BRAFV600E mutation. Its use has recently gained momentum in BRAFV600E-mutated ECD, especially in patients progressing after treatment with INFα. Dramatic clinical response was noted by Haroche et al. in a case series of three patients who had life-threatening, multi-systemic, refractory BRAFV600E-mutant disease. Vemurafenib was initiated at a dose of 1920 mg per day and then tapered to 960 mg per day. At 1 month follow-up, there was an astounding response rate of 57-70% by PET scan coupled with normalization of C-reactive protein level and improvement in clinical symptoms. The time to response on PET was notably shorter than that observed with IFNα treatment. At 4 months follow-up, the first patient had resolution of peri-aortic disease on aortic imaging, the second patient had 26-66% regression of periorbital disease on MRI, and the third patient had regression of right atrial wall infiltrate on cardiac magnetic resonance imaging (21) . Individual case reports published within the past 3 years have further supported these results in a variety of ECD presentations shown in Table II .
Highly anticipated long-term data with BRAF inhibitors is currently underway with a prospective cohort study by the Groupe Hospitalier Pitie-Salpetriere and Memorial Sloan Kettering Cancer Center expected to be completed in June of 2019 (NCT02281760). Furthermore, darafenib is being investigated by The National Cancer Institute in a phase II clinical trial looking at the efficacy of dabrafenib and trametinib in treating BRAF-mutated ECD with a focus on progression-free survival and potential resistance to combination therapy.
MEK Inhibitors
The use of MEK inhibitors, trametinib or cobimetinib, as either monotherapy or in combination with BRAF inhibitors in ECD is promising, with only a handful of cases reported in the literature. Aubart et al. described two patients with mutations in MAP2K1 receiving cobimetinib at a dose of 20 mg twice a day for 21 days of a 28 day cycle. After 7-8 months of therapy, PET imaging of the first patient showed improvement in perineal infiltration and in the second patient showed regression of dural lesions (22) . Nordmann et al. reported on the use of trametinib in combination with a BRAF inhibitor in one patient with extensive ECD previously treated with prednisone, IFNα, and IL1, and subsequently with dabrafenib once BRAFV600E mutation was identified. Despite initial response to dabrafenib, the patient relapsed after 4 months during which time a new KRAS-Q61H/wildtype BRAF activating mutation was identified. Trametinib at a dose of 2 mg daily was added to the patient's regimen with symptomatic improvement and PET response in all lesions 8 weeks after initiating treatment (23) .
Other Therapies
Cladrabine is a purine analog that inhibits DNA repair and synthesis with preferential toxicity towards lymphocytes and monocytes and induces apoptosis of monocyte-derived dendritic cells (24) . In one case report, a patient with pericardial and pleural ECD whose disease progressed on corticosteroids and pegylated IFN received cladrabine at a dose of 0.014 mg/kg followed by 0.09 mg/kg/day for 6 days. Improvement of diastolic dysfunction on echocardiogram, partial response of brain lesions on magnetic resonance imaging, and improved pulmonary function tests and computed tomographic chest results were reported after three cycles, or 6 months of treatment (25) . In another case, a patient treated with five courses of cladribine monotherapy at 5 mg/m 2 for 5 consecutive days every 4 weeks had regression of disease on PET imaging 3 months after completion of chemotherapy, complete regression of CNS disease at 2 years, and no evidence of recurrence at 12 year follow-up (26) .
Infliximab and adalimumab are TNFα inhibitors well established in the treatment of Crohn's disease, psoriasis and rheumatoid arthritis. In a small subset of patients, it has been used alone and in combination with methotrexate (27, 28) . A case series of two patients with ECD treated with infliximab showed regression of cardiac involvement (29) .
Imatinib mesylate is a tyrosine kinase inhibitor that has demonstrated antitumor activity by inhibiting KIT, breakpoint cluster region-Abelson (BCR-ABL) fusion oncogene, and platelet derived growth factor and is approved for the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors. In the context of ECD, it is postulated that it inhibits differentiation of stem cells into dendritic cells. A case report of a patient with ECD involving the lung, mediastinum and adrenals treated with imatinib at a dose of 400 mg daily described symptomatic improvement at 3 months and regression of lung involvement on PET scan at 6 months (30).
Conclusion
Recent identification of various activating mutations along the MAPK pathway in ECD have enhanced our of uptake by PET of cord lesion and skeletal changes understanding of this rare disease and aided in the classification of histiocytic disorders. This has also led to promising results based on case reports with targeted therapies signifying a possible new standard of care. The common molecular aberration, BRAFV600E, frequently shared between ECD, hairy cell leukemia and malignant melanoma, was instrumental in exploring these targeted therapies in ECD. Other effective treatments, such as IL2 in melanoma and cladribine in hairy cell leukemia, also appear to have efficacy in ECD arguing that identification of shared molecular features could be a valuable strategy at seeking new therapies especially in rare diseases where large trials are not feasible.
